Overview

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Status:
Completed
Trial end date:
2020-10-10
Target enrollment:
Participant gender:
Summary
RATIONALE: A bone marrow or umbilical cord blood transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. Giving combination chemotherapy before a donor stem cell transplant may make the transplant more likely to work. This may be an effective treatment for patients with high risk Fanconi's anemia. PURPOSE: This clinical trial is studying how well combination chemotherapy works in treating high risk patients who are undergoing a donor stem cell transplant for Fanconi's anemia.
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Antilymphocyte Serum
Busulfan
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Lenograstim
Methylprednisolone
Methylprednisolone acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Vidarabine